Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Last updated: September 10, 2024
Sponsor: Hopital of Melun
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epilepsy (Pediatric)

Epilepsy

Treatment

Isoflurane

Clinical Study ID

NCT05830864
MIR-2023-01
  • Ages > 18
  • All Genders

Study Summary

Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age > 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, sufferingrefractory status epilepticus treated by inhaled Isoflurane as third anticonvulsivetherapy

Exclusion

Exclusion Criteria:

  • post-anoxic refractory status epilepticus after cardiac arrest, withdrawal ofconsent for medical data use

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Isoflurane
Phase:
Study Start date:
June 30, 2024
Estimated Completion Date:
December 01, 2024

Study Description

Investigators will collect in 4 ICUs the data from consecutive patients hospitalized between january 2016 and january 2023. Included patient were those treated by Isoflurane for refractory status epilepticus.

Connect with a study center

  • Ch Bethune Beuvry

    Beuvry, 62660
    France

    Active - Recruiting

  • CHU Brest

    Brest, 29200
    France

    Active - Recruiting

  • GH Sud Ile de France, Hôpital de Melun-Sénart

    Melun, 77000
    France

    Active - Recruiting

  • CH Toulon - Sainte Musse

    Toulon, 83000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.